Insulin derivative
Disclosed is an acylated insulin, a pharmaceutical formulation thereof, a pharmaceutical composition thereof with a long-acting GLP-1 compound, and a medical use of the acylated insulin, the pharmaceutical formulation and the pharmaceutical composition. Compared with insulin degludec or other insulin derivatives, the acylated insulin has an unexpected, significantly increased drug effect, a longer duration of action, a longer in vivo half-life, an excellent bioavailability, as well as better physical and chemical stabilities.
1 . An insulin derivative comprising an insulin parent and an acyl moiety, wherein the insulin parent is A14E, B16H, B25H, desB30 human insulin, and the acyl moiety is linked to an amino group of a lysine residue or an N-terminal amino acid residue of the insulin parent, wherein the acyl moiety is shown as formula (D):
W1-(W2) m2 -(W3) n2 - (D),
wherein,
m2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and n2 is 11, 12, 13, 14, 15, 16, 17, or 18;
W3 is a neutral and alkylene glycol-containing amino acid residue;
W2 is an acidic amino acid residue;
W1 is a fatty diacid containing 20-24 carbon atoms, wherein formally, a hydroxyl group has been removed from one of the carboxyl groups in the fatty diacid;
W1, W2 and W3 are linked by amide bonds; and
the order of W2 and W3 presented in the formula (D) is optionally interchanged independently.
2 . The insulin derivative according to claim 1 , wherein,
n2 is 12, 13, 14, 15, 16, 17, or 18;
m2 is an integer from 1 to 6;
W1 is a fatty diacid containing 20-23 carbon atoms;
W2 is the amino acid residue of γGlu; and
W3 is —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—CH 2 —CO—.
3 . The insulin derivative according to claim 1 , wherein
W3 is: —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—CH 2 —CO—, —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —CO—, —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —CO—, —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —CO—, —HN—(CH 2 ) 3 —O—(CH 2 ) 4 —O—(CH 2 ) 3 —NH—CO—, —HN—(CH 2 ) 3 —O—(CH 2 ) 4 —O—(CH 2 ) 3 —NH—CO—CH 2 —O—CH 2 —CO—, —HN—(CH 2 ) 3 —O—(CH 2 ) 4 —O—(CH 2 ) 3 —NH—CO—(CH 2 ) 2 —CO—, —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—CH 2 —CO—CH 2 —O—CH 2 —CO—, —HN—(CH 2 ) 3 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 3 —NH—CO—(CH 2 ) 2 —CO—, —HN—(CH 2 ) 3 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 3 —NH—CO—CH 2 —O—CH 2 —CO—, —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —NH—CO—(CH 2 ) 2 —CO—, —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —NH—CO—CH 2 —O—CH 2 —CO—, —HN—(CH 2 ) 3 —O—(CH 2 ) 2 —O—(CH 2 ) 2 —O—(CH 2 ) 3 —NH—CO—CH 2 —O—CH 2 —CO—, —HN—(CH 2 ) 3 —O—(CH 2 ) 3 —O—CH 2 —CO—, or —HN—(CH 2 ) 4 —O—(CH 2 ) 4 —O—CH 2 —CO—; or W3′ is —HN—(CH 2 —CH 2 —O) 20 —CH 2 —CO—, —HN—(CH 2 —CH 2 —O) 22 —CH 2 —CO—, —HN—(CH 2 —CH 2 —O) 24 —CH 2 —CO—, or —HN—(CH 2 —CH 2 —CH 2 —O) 15 —CH 2 —CO—; and/or
W2 is an amino acid residue selected from the group consisting of γGlu, αGlu, βAsp, αAsp, γ-D-Glu, α-D-Glu, β-D-Asp and α-D-Asp; and/or
W1 is HOOC—(CH 2 ) 18 —CO—, HOOC—(CH 2 ) 19 —CO—, HOOC—(CH 2 ) 20 —CO—, HOOC—(CH 2 ) 21 —CO— or HOOC—(CH 2 ) 22 —CO—.
4 . The insulin derivative according to claim 1 , wherein the formula (D) is linked to the amino group of the lysine residue or the N-terminal amino acid residue of the insulin parent via the C-terminal of W3.
5 . The insulin derivative according to claim 1 , wherein the acyl moiety is linked to an ε amino group of the lysine residue of the insulin parent.
6 . The insulin derivative according to claim 1 , wherein the insulin derivative is selected from the group consisting of A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-12×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-12×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-11×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-11×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-12×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tricosanedioyl-γGlu-12×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tetracosanedioyl-γGlu-12×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-13×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-14×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-15×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-13×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-14×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-15×OEG), desB30 human insulin; and A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-18×OEG), desB30 human insulin.
7 . A pharmaceutical composition, comprising the insulin derivative according to claim 1 , and one or more pharmaceutically acceptable excipients.
8 . The pharmaceutical composition according to claim 7 , wherein the pharmaceutical composition comprises at least 1.5 moles of zinc ions/6 moles of the insulin derivative; and/or the pharmaceutical composition has a pH value in the range from 6.5 to 8.5.
9 . The pharmaceutical composition according to claim 8 , wherein the pharmaceutical composition further comprises glycerol, phenol, m-cresol, NaCl and/or Na 2 HPO 4 .
10 . The pharmaceutical composition according to claim 9 , wherein the content of glycerol is no more than about 2.5% (w/w); and/or
the content of phenol is about 16-80 mM; and/or
the content of NaCl is about 0-150 mM; and/or
the content of Na 2 HPO 4 is about 0-75 mM; and/or
the content of the insulin derivative is more than about 0.3 mM.
11 . The pharmaceutical composition according to claim 7 , wherein the insulin derivative is A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-11×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-12×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-11×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-12×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-13×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-14×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-13×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-14×OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-15×OEG), desB30 human insulin; or A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-15×OEG), desB30 human insulin.
12 . The pharmaceutical composition according to claim 7 , comprising about 0.6 mM or 1.2 mM of the insulin derivative, 1.7% (w/w) glycerol, about 45 mM phenol, about 10 mM m-cresol, about 6.5 moles of zinc ions/6 moles of the insulin derivative and about 20 mM sodium chloride and having a pH value of about 7.0-8.0.
13 . The pharmaceutical composition according to claim 7 , comprising about 0.6-4.2 mM of the insulin derivative, about 1% to about 2% (w/w) glycerol, about 15-60 mM phenol, about 0-25 mM m-cresol, about 1.5-7.0 moles of zinc ions/6 moles of the insulin derivative, about 10-120 mM sodium chloride and having a pH value of about 7.0-8.0.
14 . The pharmaceutical composition according to claim 7 , comprising about 1.2-1.5 mM of the insulin derivative, about 1.5%-1.7% (w/w) glycerol, about 45-60 mM phenol, about 0-10 mM m-cresol, about 2.2-2.5 moles of zinc ions/6 moles of the insulin derivative, and about 20 mM sodium chloride and having a pH value of about 7.0-8.0.
15 . The pharmaceutical composition according to claim 7 , further comprising a rapid-acting insulin.
16 . The pharmaceutical composition according to claim 15 , wherein the rapid-acting insulin is one or more insulins selected from Asp B28 human insulin, Lys B28 Pro B29 human insulin, Lys B3 Glu B29 human insulin, human insulin, and desB30 human insulin.
17 . A method for treating diabetes, hyperglycemia, and/or impaired glucose tolerance, wherein the method comprises administering a therapeutically effective amount of the insulin derivative according to claim 1 .
18 . The insulin derivative according to claim 1 , wherein,
W3 is —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—CH 2 —CO—.
19 . The insulin derivative according to claim 1 , wherein,
n2 is 11, 12, 13, 14, 15, or 16; and
m2 is 1, 2, 3 or 4.
20 . The insulin derivative according to claim 1 , wherein,
n2 is 11, 12, 13, 14, or 15;
m2 is 1 or 2;
W1 is a fatty diacid containing 20, 21 or 22 carbon atoms, wherein formally, a hydroxyl group has been removed from one of the carboxyl groups in the fatty diacid;
W2 is the amino acid residue of γGlu; and
W3 is —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—CH 2 —CO—.
21 . The insulin derivative according to claim 1 , wherein,
n2 is 11, 12, 13, or 14;
m2 is 1 or 2;
W1 is HOOC—(CH 2 ) 18 —CO—, HOOC—(CH 2 ) 19 —CO—, HOOC—(CH 2 ) 20 —CO— or HOOC—(CH 2 ) 21 —CO—;
W2 is the amino acid residue of γGlu; and
W3 is —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—CH 2 —CO—.
22 . The insulin derivative according to claim 1 , wherein,
n2 is 11, 12, or 13;
m2 is 1 or 2;
W1 is HOOC—(CH 2 ) 18 —CO—, HOOC—(CH 2 ) 19 —CO—, or HOOC—(CH 2 ) 20 —CO—;
W2 is the amino acid residue of γGlu; and
W3 is —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—CH 2 —CO—.
23 . The insulin derivative according to claim 1 , wherein,
n2 is 12;
m2 is 1 or 2;
W1 is HOOC—(CH 2 ) 18 —CO—, HOOC—(CH 2 ) 19 —CO—, or HOOC—(CH 2 ) 20 —CO—;
W2 is the amino acid residue of γGlu; and
W3 is —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—CH 2 —CO—.
24 . An insulin derivative comprising an A14E, B16H, B25H, desB30 human insulin having an A-chain of SEQ ID NO: 3 and a B-chain of SEQ ID NO: 4, and an acyl moiety, wherein the acyl moiety has the formula (A):
III-(II) m -(I) n - (A)
wherein,
I is —HN—(CH 2 ) 2 —O—(CH 2 ) 2 —O—CH 2 —CO—;
II is the amino acid residue of γGlu;
III is HOOC—(CH 2 ) 18 —CO—, HOOC—(CH 2 ) 19 —CO—, or HOOC—(CH 2 ) 20 —CO—;
m is an integer of 1, and
n is 12,
wherein,
I, II, III are linked together by amide bonds in the acyl moiety, and
the acyl moiety is linked to the ε amino group of the lysine residue at position B29 of the B-chain via the C-terminal of I.
25 . A pharmaceutical composition, comprising the insulin derivative of claim 24 , and one or more pharmaceutically acceptable excipients.
26 . A method for treating diabetes, hyperglycemia, and/or impaired glucose tolerance, comprising administering to a subject in need thereof a therapeutically effective amount of the insulin derivative of claim 24 .
27 . The insulin derivative of claim 24 , selected from the group consisting of:
A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-12×OEG), desB30 human insulin;
A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-12×OEG), desB30 human insulin; and
A14E, B16H, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-12×OEG), desB30 human insulin.
28 . The insulin derivative of claim 27 , comprising:
A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-12×OEG), desB30 human insulin; or
A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-12×OEG), desB30 human insulin.
29 . The insulin derivative of claim 27 , comprising A14E, B16H, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-12×OEG), desB30 human insulin.
30 . A pharmaceutical composition, comprising the insulin derivative of claim 27 and one or more pharmaceutically acceptable excipients.
31 . The pharmaceutical composition of claim 30 , wherein the insulin derivative comprises:
A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-12×OEG), desB30 human insulin; or
A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-12×OEG), desB30 human insulin.
32 . The pharmaceutical composition of claim 30 , wherein the insulin derivative comprises A14E, B16H, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-12×OEG), desB30 human insulin.
33 . A method for treating diabetes, hyperglycemia, and/or impaired glucose tolerance, comprising administering to a subject in need thereof a therapeutically effective amount of the insulin derivative of claim 27 .
34 . The method of claim 33 , wherein the insulin derivative comprises:
A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-12×OEG), desB30 human insulin; or
A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-12×OEG), desB30 human insulin.
35 . The method of claim 33 , wherein the insulin derivative comprises A14E, B16H, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-12×OEG), desB30 human insulin.
36 . The insulin derivative of claim 27 , having the following structure:
37 . A pharmaceutical composition, comprising the insulin derivative of claim 36 and one or more pharmaceutically acceptable excipients.
38 . A method for treating diabetes or hyperglycemia, comprising administering to a subject in need thereof a therapeutically effective amount of the insulin derivative of claim 36 .
39 . A method for treating impaired glucose tolerance, comprising administering to a subject in need thereof a therapeutically effective amount of the insulin derivative of claim 36 .
40 . An insulin derivative, having the following structure:
41 . A pharmaceutical composition, comprising the insulin derivative of claim 40 and one or more pharmaceutically acceptable excipients.
42 . A method for treating diabetes or hyperglycemia, comprising administering to a subject in need thereof a therapeutically effective amount of the insulin derivative of claim 40 .
43 . A method for treating impaired glucose tolerance, comprising administering to a subject in need thereof a therapeutically effective amount of the insulin derivative of claim 40 .